JP3890544B2 - New indole glycosides - Google Patents
New indole glycosides Download PDFInfo
- Publication number
- JP3890544B2 JP3890544B2 JP11330497A JP11330497A JP3890544B2 JP 3890544 B2 JP3890544 B2 JP 3890544B2 JP 11330497 A JP11330497 A JP 11330497A JP 11330497 A JP11330497 A JP 11330497A JP 3890544 B2 JP3890544 B2 JP 3890544B2
- Authority
- JP
- Japan
- Prior art keywords
- meoh
- extract
- currantside
- glucose
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、エビネラン(Calanthe discolor Lindl.)から単離したインドール配糖体に関するものである。
【0002】
【従来の技術】
エビネランのアルコール溶液抽出物が、発毛・育毛剤として著効を示すことは知られている(特開平5−294813号公報)。しかしながら、エビネラン抽出液含有成分は、まだ十分に解明されてなく、有効成分の特定にいたっていない現状である。
【0003】
【発明が解決しようとする課題】
本発明者らは、エビネランからのアルコール抽出液の分画成分を精査し、生理的に有用な活性をもつ新規インドール配糖体を単離することに成功し、本発明にいたった。
【0004】
すなわち、本発明は、エビネランから単離した血流促進作用及び美白作用のある新規インドール配糖体を提供することを目的としている。
【0005】
【課題を解決するための手段】
上記目的を達成した本発明の新規インドール配糖体は、化1で示す3−o−β−D−グルコピラノシル(1→6)−β−D−グルコピラノシルインドール(3−o−β−D−glucopyranosyl(1→6)−β−D−glucopyranocyl indol)(以下「カラントサイドA/calanthoside A」という)からなることを特徴としている。
【0006】
【化1】
【0007】
【発明の実施の形態】
本発明のカラントサイドAは、次のようにして製造できる。エビネランの根茎を細切りした後、例えばメタノールで熱時抽出し、メタノール抽出エキスを得る。得られたメタノール抽出エキスを酢酸エチルと水(1:1)で分配抽出する。次いで水移行部を逆相シリカゲルカラムクロマトガラフィーに付し、水、メタノールで順次溶出し、メタノール溶出部を得る。メタノール溶出部を順相シリカゲルカラムクロマトグラフィーで分画し、さらに順相シリカゲルカラムガスクロマトグラフィーで分画し、逆相高速液体クロマトグラフィーを用いて繰り返し分離することにより、カラントサイドAが単離される。
【0008】
カラントサイドAは、後述する試験例1から明らかなように、ラットの皮膚血流促進作用を有意に増加させることが明らかとなり、育毛剤等の用途が期待できる。また皮膚美白作用は、皮膚が黒くなるのを防ぐ意味で、皮膚でのメラミン産生の抑制をみるのがひとつの指標となる。メラニンはチロシンあるいはドーパからチロシナーゼという酵素によって産生されるので、この酵素活性を抑制することが美白につながる。後述の試験例2に示すように、この酵素活性を抑制する抗チロシナーゼ活性を測定した結果、カラントサイドAは、比較的強い抗チロシナーゼ効果を示し、美白乳液、クリーム等の化粧料としての利用が期待できる。
【0009】
【実施例】
(単離)
宮崎産エビネ新鮮根茎(7.5kg)を細切りした後、MeOH(18リットル)で熱時抽出を計3回おこなった。MeOH抽出液3回分をあわせて減圧下溶媒留去し、MeOH抽出エキス(330g,4.4%)を得た。エビネMeOH抽出工キス(300g)をAcOEt−H2O(1:1)で分配して、AcOEt層移行部(75g,1.0%)、H2O層移行部(225g,3.0%)を得た。得られたH2O層移行部エキスを逆相シリカゲルカラムクロマトグラフィー[1.0kg,H2O→MeOH]で糖除去し、MeOH流出部エキス(13g,1.7%)を得た。MeOH流出部エキス13gを順相シリカゲルカラムクロマトグラフィー{1.0kg,[CHCl3:MeOH=10:1→3:1→1:1]→[CHCl3:MeOH:H2O=65:35:10(下層)→6:4:1]→MeOH}で分離し、Fr.1(170mg,0.0023%)、Fr.2(41mg,0.0005%)、Fr.3(48mg,0.0006%)、Fr.4(234mg,0.0031%)、Fr.5(4100mg,0.055%)、Fr.6(2700mg,0.036%)、Fr.7(2000mg,0.027%)、Fr.8(4000mg,0.053%)を得た。Fr.7(4300mg,0.057%)を順相シリカゲルカラムクロマトグラフィー[40g,CHCl3:MeOH:H2O=7:3:1(下層)→65:35:10(下層)→6:4:1]で分画し、さらに逆相高速液体クロマトグラフイー(HPLC)[カラム;YMC−Pack R&D ODS−5(250×20mmi.d.),溶媒;MeCN−H2O(30:70,v/v),流速;9.0ml/min]、逆相高速液体クロマトグラフィー(HPLC)[カラム;YMC−Pack R&D ODS−5(250×20mm i.d.),溶媒;MeOH−H2O(25:75,v/v),流速;9.0ml/min]で繰り返し分離精製し、カラントサイドA(81.9mg,0.0011%)を得た。
【0010】
【分析例1】
(同定)
カラントサイドAは正の旋光性を示す淡黄色粉末で、分析結果は下記のとおりである。
カラントサイドA:非晶粉末
旋光性:[α]D 25+164.0゜(c=0.01,MeOH)
高分解能FAB−MS(m/z)
次式計算値 C20H28NO11(M+H)+:458.1638
実測値 :458.1650
IR(KBr,cm−1):
3490,1618,1554,1458,1028
UV(c=0.0006,MeOH,nm,log ε):
282(4.7),224(5.4)
1H−NMR(CD3OD,500MHz,δ):
4.40(1H,d,J=7.6Hz,1”−H),
4.74(1H,d,J=7.3Hz,1’−H)
6.97(1H,ddd,J=1.3,6.9,7.9Hz,5−H),
7.07(1H,ddd,J=1.3,6.9,8.3Hz,6−H)
7.15(1H,s,2−H),
7.27(1H,dd,J=1.3,8.3Hz,7−H),
7.67(1H,dd,J=1.3,7.9Hz,4−H)
13C−NMR(CD3OD,125MHz,δc):
C−1 , C−2 112.2,
C−3 138.8, C−4 118.6,
C−5 119.5, C−6 122.8,
C−7 112.4, C−8 135.4,
C−9 121.3, C−10 ,
C−1’ 105.4 C−2’ 75.0,
C−3’ 77.9 C−4 71.5,
C−5’ 77.3 C−6’ 69.9,
C−1” 104.7 C−2” 75.1,
C−3” 77.9 C−4” 71.5,
C−5” 77.9 C−6” 62.7,
Positive−mode FAB−MS(m/z):
480(M+Na)+
Negative−mode FAB−MS(m/z):
456(M−H)−
【0011】
【分析例2】
(糖の同定)
カラントサイドA(3mg)の5%H2SO4−ジオキサン(dioxane)(1:1,v/v,1.0ml)溶液を窒素気流下、加熱還流し、2時間攪拌した。反応液を陰イオン交換樹脂IRA−400(OH−form)で中和し、樹脂を濾別後、溶媒を減圧留去し、粗生成物(2.8mg)を得た。粗生成物を逆相シリカゲルカラムクロマトグラフィー(0.2g,H2O→MeOH)で分離精製し、溶媒を減圧留去し、粗生成物(1.0mg)を得た。得られた粗生成物のピリジン溶液に、L−システィンメチルエステルヒドロクロライド(0.3mg)を加え60℃で1時間攪拌し、つづいてN,O−ビス(トリメチルシリル)トリフルオロアセトアミド(0.3ml)を加え60℃で1時間攪拌し、濾別後、GC用サンプルとして以下に示す条件でGC分析を行った。
GC条件
column:Supeluco STBTM−1(0.25mm×30m)
Injector temp:230℃
Detector temp:230℃
Column temp:230℃
He flow rate:15ml/min
保持時間(tr)
D−Glucose:24.15
L−Glucose:25.46
【0012】
前記分析例1及び分析例2から、カラントサイドAは、FAB−MS及び高分解能FAB−MSにより、分子式C20H27NO11を有することが明らかになった。またIRスペクトルにおいて、水酸基(3490cm−1)及びピロール環(1554cm−1)の存在が示唆され、1H−NMR及び13C−NMRスペクトルの解析により、β結合した2個のグルコース[δ4.40(d,J=7.6),δc104.7]、[δ4.74(d,J=7.3),δc105.4]の存在が確認された。カラントサイドAを、H2SO4−ジオギサンで酸加水分解すると、d−グルコース(d−glucose)が得られ、カラントサイドAの1H−NMR及び13C−NMRスペクトルを文献記載の化2に示すインディカン(indican)と比較すると、グルコースの6位炭素のシグナルが低磁場に、5位炭素のシグナルが高磁場にグルコシル化シフトしていたことから、カラントサイドAは、化1に示すように、インディカンのグルコースの6位水酸基にもう1分子のグルコースが結合している化合物であることが示唆された。
【0013】
またカラントサイドAの1H−1H,13C−1HCOSY及び1H−1H,13C−1HOHAHAスペクトルの解析の結果、糖部のシグナルが完全に帰属され、糖の結合様式はアノメリック水素のカップリング定数及びアノメリック炭素の化学シフト[δ4.40(d,J=7.6),δc104.7]、[δ4.74(d,J=7.3),δc105.4]の考察から、2個のグルコースはともにβ結合していることが明らかとなった。さらに、HMBCスペクトルにおいて、グルコースのアノメリック水素(δ4.74,1H,d,J=7.3)とインドール環部の3位炭素(δc138.8)、もう一方のグルコースのアノメリック水素(δ4.40,1H,d,J=7.6)とグルコース6’位炭素(δc69.9)との間に相関が観測されたことから、カラントサイドAはインディカンのグルコースの6’位にグルコースが結合した3−o−β−D−グルコピラノシル(1→6)−β−D−グルコピラノシルインドール(化1)であると決定した。
【0014】
【化2】
【0015】
【参考例】
(単離)
宮崎産エビネ新鮮葉(2.9kg)をMeOH(8リットル)で熱時抽出を計3回行った。MeOH抽出液の3回分をあわせて、減圧下溶媒流去し、MeOH抽出エキス(150g,5.2%)を得た。エビネMeOH抽出エキス(150g)をAcOEt−H2O(1:1)で分配し、AcOEt移行部(62g,2.1%)を得た。得られたAcOEt移行部エキスを順相シリカゲルカラムクロマトグラフィー{1.0kg,CHCl3→[CHCl3:MeOH=50:1→10:1→5:1]→MeOH}で分離し、Fr.1(10.5g,0.36%)、Fr.2(5.4g,0.19%)、Fr.3(14.2g,0.49%)、Fr.4(8.0g,0.28%)、Fr.5(10.7g,0.37%)、Fr.6(10.3g,0.36%)を得た。Fr.3(14.2g)をさらに順相シリカゲルカラムクロマトグラフィー[15g,CHCl3:MeOH=20:1→10:1→5:1→MeOH]、順相シリカゲルカラムクロマトグラフィー[15g,CHCl3:MeOH=20:1→10:1→5:1→MeOH]で順次分画し、インジルビン(indirubin、化3)(128.0mg,0.0044%)、トリプタントリン(tryptanthrin)化4)(6.8mg,0.0002%)を得た。Fr.5(10.7g)を逆相シリカゲルカラムクロマトグラフィー[130g,MeOH:H2O(40:60→50:50→80:20,v/v),逆相高速液体クロマトグラフィー[カラム:YMC−pack R&D ODS−5(250×20mm i.d.),溶媒;MeOH(45:55,v/v)流速;9.0ml/min]で順次分画し、ヴォミフォリオール(vomifoliol、化5)(38.6mg,0.0013%)を得た。ここで得られた化合物は、1H、13C−NMRデータ及びTLCを比較し同定した結果、いずれも前述の既知化合物であることが明らかになった。
【0016】
【化3】
【0017】
【化4】
【0018】
【化5】
【0019】
【試験例1】
(ラット皮膚血流促進作用)
実験動物として、SLc:ウィスター系雄性ラット(体重180〜200g)を用いた。皮膚血流量は、レーザードップラー血流計(Laser Doppler Flowmeter PF2B,Perimed)を用いて測定した。ラットの背部を剪毛し、翌日にウレタン(1g/kg)麻酔下でラットの皮膚血流量を測定し、前値とした。前値測定直後に被験液25μl(50%エタノール溶液)を前値測定部位に塗布し、その20分、40分、及び60分後に塗布部位の皮膚血流量を再度測定し、前値に対する増加率を算出した。なお、対照群には50%エタノール溶液を塗布した。被験液には、実施例のエビネMeOH抽出エキス(CDM−ext)(0.5%,2.0%)、本発明のカラントサイドA(CDH2)(0.2%)、参考例の既知物質インジルビン(indirubin)(0.2%)を用いた。結果を表1及び図1に示す。
【0020】
【表1】
【0021】
表1から明らかなように、エビネMeOH抽出エキスは、0.5%、2.0%のいずれにおいても、ラット皮膚血流量を顕著に増加させた。また図1に示すように、本発明のカラントサイドAは、20分で皮膚血流量を有意に増加させた。インジルビンにも同様の促進作用は認められるが、有意ではなかった。
【0022】
【試験例2】
(美白作用)
MasonとPetersonの方法に準じて、以下の通り実験した。すなわち、被験液0.5mlにL−ドーパ溶液(pH6.8PBS中、0.03%)0.5mlを加え、25℃、10分間インベキュートし、さらにマッシュルーム由来のチロシナーゼ溶液(pH6.8PBS中、45U/ml)0.5mlを添加し、25℃5分間インベキュートした。反応後475nmにおける吸光度(D1)を測定した。別に、L−ドーパ溶液を添加せずに同様な操作を行い、吸光度(D2)を測定し、被験薬無添加におけるドーパクロムの生成量としての吸光度(D3)を測定した。このD1、D2、D3を用いで、下記の式によりドーパクロム生成阻害率を求め、チロシナーゼ活性の指標とした。被験液には、実施例のエビネMeOH抽出エキス(CDM−ext)、実施例の酢酸エチル層移行部(AcOEtphase)、水層移行部(H2Ophase)、本発明のカラントサイドA(CDH2)、及び対照群として陽性対照薬のコウジ酸(kojic acid)を用いた。結果を表2に示す。
【0023】
【式1】
【0024】
【表2】
【0025】
表2から明らかなように、エビネMeOH抽出エキス、酢酸エチル層移行部、水層移行部は、ともに用量依存的に強い抗チロシナーゼ活性を示した。陽性対照群のコウジ酸も強い抗チロシナーゼ活性を示した。収率から考えあわせると、抗チロシナーゼ活性有効成分は、主として水層移行部にあると考えられるが、本発明のカラントサイドAも、表3に示すように、比較的強い抗チロシナーゼ活性を示した。
【0026】
【発明の効果】
本発明によれば、新規カラントサイドAは皮膚血流促進作用を有し、育毛剤等の有用な用途が期待できる。また皮膚の美白作用も認められ、化粧料等への利用も可能である。
【図面の簡単な説明】
【図1】エビネランから単離されたカラントサイドAとインジルビンのラット皮膚血流促進効果を示すグラフである。
【化1】
【化2】
【化3】
【化4】
【化5】
【数1】
【表1】
【表2】
【表3】
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an indole glycoside isolated from Evinelane (Calenthe discol Lindl.).
[0002]
[Prior art]
It is known that an alcoholic solution extract of evinelan shows a remarkable effect as a hair growth / hair growth agent (Japanese Patent Laid-Open No. 5-294913). However, the component containing the ebinelan extract has not yet been fully elucidated, and the current status has not yet been determined.
[0003]
[Problems to be solved by the invention]
The inventors of the present invention have succeeded in isolating a novel indole glycoside having a physiologically useful activity by examining the fraction components of an alcohol extract from ebinellan, and have arrived at the present invention.
[0004]
That is, an object of the present invention is to provide a novel indole glycoside having blood flow promoting action and whitening action isolated from ebinelan.
[0005]
[Means for Solving the Problems]
The novel indole glycoside of the present invention that has achieved the above object is a 3-o-β-D-glucopyranosyl (1 → 6) -β-D-glucopyranosylindole (3-o-β- It is characterized by comprising D-glucopyranosyl (1 → 6) -β-D-glucopyranyl indol (hereinafter referred to as “currantside A / calanthoside A”).
[0006]
[Chemical 1]
[0007]
DETAILED DESCRIPTION OF THE INVENTION
The currant side A of the present invention can be produced as follows. Ebinelan rhizomes are chopped and then extracted with methanol, for example, to obtain a methanol extract. The obtained methanol extract is partitioned and extracted with ethyl acetate and water (1: 1). Next, the water transfer part is subjected to reverse phase silica gel column chromatography and eluted with water and methanol sequentially to obtain a methanol elution part. The methanol eluate is fractionated by normal phase silica gel column chromatography, further fractionated by normal phase silica gel column gas chromatography, and repeatedly separated using reverse phase high performance liquid chromatography to isolate currantside A. .
[0008]
As will be apparent from Test Example 1 described later, currant side A has been shown to significantly increase the skin blood flow promoting action in rats, and can be expected to be used as a hair restorer. In addition, the skin whitening effect is to prevent the skin from becoming dark, and one measure is to check the suppression of melamine production in the skin. Since melanin is produced from tyrosine or dopa by an enzyme called tyrosinase, inhibiting this enzyme activity leads to whitening. As shown in Test Example 2 to be described later, as a result of measuring the anti-tyrosinase activity that suppresses this enzyme activity, Currantside A shows a relatively strong anti-tyrosinase effect and can be used as a cosmetic such as whitening milky lotion and cream. I can expect.
[0009]
【Example】
(Isolation)
After shredding fresh shrimp from Miyazaki (7.5 kg), hot extraction with MeOH (18 liters) was performed three times in total. The three MeOH extracts were combined and evaporated under reduced pressure to give a MeOH extract (330 g, 4.4%). Ebine MeOH extraction kiss (300 g) was distributed with AcOEt-H 2 O (1: 1), AcOEt layer transition part (75 g, 1.0%), H 2 O layer transition part (225 g, 3.0%) ) The obtained H 2 O layer transition part extract was subjected to sugar removal by reverse phase silica gel column chromatography [1.0 kg, H 2 O → MeOH] to obtain a MeOH effluent part extract (13 g, 1.7%). 13 g of MeOH effluent extract was subjected to normal phase silica gel column chromatography {1.0 kg, [CHCl 3 : MeOH = 10: 1 → 3: 1 → 1: 1] → [CHCl 3 : MeOH: H 2 O = 65: 35: 10 (lower layer) → 6: 4: 1] → MeOH}, Fr. 1 (170 mg, 0.0023%), Fr. 2 (41 mg, 0.0005%), Fr. 3 (48 mg, 0.0006%), Fr. 4 (234 mg, 0.0031%), Fr. 5 (4100 mg, 0.055%), Fr. 6 (2700 mg, 0.036%), Fr. 7 (2000 mg, 0.027%), Fr. 8 (4000 mg, 0.053%) was obtained. Fr. 7 (4300 mg, 0.057%) was subjected to normal phase silica gel column chromatography [40 g, CHCl 3 : MeOH: H 2 O = 7: 3: 1 (lower layer) → 65: 35: 10 (lower layer) → 6: 4: 1], and further reversed-phase high performance liquid chromatography (HPLC) [column; YMC-Pack R & D ODS-5 (250 × 20 mmid)], solvent; MeCN-H 2 O (30:70, v / V), flow rate: 9.0 ml / min], reverse phase high performance liquid chromatography (HPLC) [column; YMC-Pack R & D ODS-5 (250 × 20 mm id), solvent; MeOH—H 2 O ( 25:75, v / v), flow rate; 9.0 ml / min], repeatedly and purified to obtain currantside A (81.9 mg, 0.0011%).
[0010]
[Analysis Example 1]
(Identification)
Currantside A is a light yellow powder exhibiting positive optical rotation, and the analysis results are as follows.
Currant side A: Amorphous powder optical rotation: [α] D 25 + 164.0 ° (c = 0.01, MeOH)
High resolution FAB-MS (m / z)
Calculated value of the following formula: C 20 H 28 NO 11 (M + H) + : 458.1638
Actual value: 458.1650
IR (KBr, cm −1 ):
3490, 1618, 1554, 1458, 1028
UV (c = 0.006, MeOH, nm, log ε):
282 (4.7), 224 (5.4)
1 H-NMR (CD 3 OD, 500 MHz, δ):
4.40 (1H, d, J = 7.6 Hz, 1 ″ −H),
4.74 (1H, d, J = 7.3 Hz, 1′−H)
6.97 (1H, ddd, J = 1.3, 6.9, 7.9 Hz, 5-H),
7.07 (1H, ddd, J = 1.3, 6.9, 8.3 Hz, 6-H)
7.15 (1H, s, 2-H),
7.27 (1H, dd, J = 1.3, 8.3 Hz, 7-H),
7.67 (1H, dd, J = 1.3, 7.9 Hz, 4-H)
13 C-NMR (CD 3 OD, 125 MHz, δc):
C-1, C-2 112.2,
C-3 138.8, C-4 118.6
C-5 119.5, C-6 122.8,
C-7 112.4, C-8 135.4
C-9 121.3, C-10,
C-1 ′ 105.4 C-2 ′ 75.0,
C-3 ′ 77.9 C-4 71.5,
C-5 ′ 77.3 C-6 ′ 69.9,
C-1 "104.7 C-2" 75.1,
C-3 "77.9 C-4" 71.5,
C-5 "77.9 C-6" 62.7,
Positive-mode FAB-MS (m / z):
480 (M + Na) +
Negative-mode FAB-MS (m / z):
456 (M−H) −
[0011]
[Analysis Example 2]
(Identification of sugar)
A solution of currantside A (3 mg) in 5% H 2 SO 4 -dioxane (1: 1, v / v, 1.0 ml) was heated to reflux under a nitrogen stream and stirred for 2 hours. The reaction solution was neutralized with an anion exchange resin IRA-400 (OH - form), the resin was filtered off, and the solvent was distilled off under reduced pressure to obtain a crude product (2.8 mg). The crude product was separated and purified by reverse phase silica gel column chromatography (0.2 g, H 2 O → MeOH), and the solvent was distilled off under reduced pressure to obtain a crude product (1.0 mg). L-cysteine methyl ester hydrochloride (0.3 mg) was added to the resulting pyridine solution of the crude product and stirred at 60 ° C. for 1 hour, followed by N, O-bis (trimethylsilyl) trifluoroacetamide (0.3 ml). ) And stirred at 60 ° C. for 1 hour, and after filtration, GC analysis was performed under the conditions shown below as a sample for GC.
GC condition column: Superluco STB TM -1 (0.25 mm x 30 m)
Injector temp: 230 ° C
Detector temp: 230 ° C
Column temp: 230 ° C
He flow rate: 15 ml / min
Holding time ( tr )
D-Glucose: 24.15
L-Glucose: 25.46
[0012]
From analysis example 1 and analysis example 2, it was revealed that currant side A has molecular formula C 20 H 27 NO 11 by FAB-MS and high resolution FAB-MS. In addition, in the IR spectrum, the presence of a hydroxyl group (3490 cm −1 ) and a pyrrole ring (1554 cm −1 ) is suggested, and analysis of 1 H-NMR and 13 C-NMR spectra shows two β-bonded glucose [δ 4.40. The presence of (d, J = 7.6), δc104.7], [δ4.74 (d, J = 7.3), δc105.4] was confirmed. When the currantside A is hydrolyzed with H 2 SO 4 -diogisan, d-glucose (d-glucose) is obtained, and the 1 H-NMR and 13 C-NMR spectra of currantside A are converted into the chemical formula 2 described in the literature. Compared to the indican shown, the 6th carbon signal of glucose was shifted to a low magnetic field and the 5th carbon signal was glucosylated to a high magnetic field. It was suggested that this is a compound in which another molecule of glucose is bonded to the 6-position hydroxyl group of glucose of indican.
[0013]
The 1 H- 1 H, 13 C- 1 HCOSY and 1 H- 1 H, 13 C- 1 HOHAHA result of the analysis of the spectrum of currant side A, the signal of the sugar portion is attributed completely binding modes sugar anomeric Coupling constants of hydrogen and chemical shifts of anomeric carbon [δ4.40 (d, J = 7.6), δc104.7], [δ4.74 (d, J = 7.3), δc105.4] Thus, it was revealed that the two glucoses were both β-bonded. Furthermore, in the HMBC spectrum, the anomeric hydrogen of glucose (δ 4.74, 1H, d, J = 7.3), the 3-position carbon (δc 138.8) of the indole ring portion, and the anomeric hydrogen of the other glucose (δ 4.40). , 1H, d, J = 7.6) and glucose 6'-position carbon (δc69.9), the current was bound to 6'-position of indican glucose. 3-o-β-D-glucopyranosyl (1 → 6) -β-D-glucopyranosylindole (Chemical Formula 1).
[0014]
[Chemical 2]
[0015]
[Reference example]
(Isolation)
Miyazaki-grown shrimp fresh leaves (2.9 kg) were extracted with MeOH (8 liters) with hot extraction three times. Three portions of the MeOH extract were combined, and the solvent was removed under reduced pressure to obtain a MeOH extract (150 g, 5.2%). Ebine MeOH extract (150 g) was distributed with AcOEt-H 2 O (1: 1) to obtain an AcOEt transition part (62 g, 2.1%). The obtained AcOEt transition part extract was separated by normal phase silica gel column chromatography {1.0 kg, CHCl 3 → [CHCl 3 : MeOH = 50: 1 → 10: 1 → 5: 1] → MeOH}. 1 (10.5 g, 0.36%), Fr. 2 (5.4 g, 0.19%), Fr. 3 (14.2 g, 0.49%), Fr. 4 (8.0 g, 0.28%), Fr. 5 (10.7 g, 0.37%), Fr. 6 (10.3 g, 0.36%) was obtained. Fr. 3 (14.2 g) was further subjected to normal phase silica gel column chromatography [15 g, CHCl 3 : MeOH = 20: 1 → 10: 1 → 5: 1 → MeOH], normal phase silica gel column chromatography [15 g, CHCl 3 : MeOH = 20: 1-> 10: 1-> 5: 1-> MeOH] in order, indirubin (chemical formula 3) (128.0 mg, 0.0044%), tryptanthrin (4) (6. 8 mg, 0.0002%) was obtained. Fr. 5 (10.7 g) was subjected to reverse phase silica gel column chromatography [130 g, MeOH: H 2 O (40: 60 → 50: 50 → 80: 20, v / v), reverse phase high performance liquid chromatography [column: YMC- pack R & D ODS-5 (250 × 20 mm id), solvent; MeOH (45:55, v / v) flow rate; 9.0 ml / min], sequentially fractionated, and vomifoliol (chemical formula 5). ) (38.6 mg, 0.0013%). As a result of comparing and identifying 1 H, 13 C-NMR data and TLC, it was revealed that all of the compounds obtained here were the aforementioned known compounds.
[0016]
[Chemical 3]
[0017]
[Formula 4]
[0018]
[Chemical formula 5]
[0019]
[Test Example 1]
(Rat skin blood flow promoting action)
As experimental animals, SLc: Wistar male rats (body weight 180 to 200 g) were used. The skin blood flow was measured using a laser Doppler flowmeter (Laser Doppler Flowmeter PF2B, Perimed). The rat's back was shaved and the skin blood flow of the rat was measured on the next day under urethane (1 g / kg) anesthesia to obtain the previous value. Immediately after measuring the previous value, apply 25 μl of the test solution (50% ethanol solution) to the previous value measurement site, measure the blood flow at the application site again 20 minutes, 40 minutes, and 60 minutes later, and increase rate relative to the previous value. Was calculated. A 50% ethanol solution was applied to the control group. In the test solution, Ebine MeOH extract of Example (CDM-ext) (0.5%, 2.0%), Currantside A (CDH2) (0.2%) of the present invention, known substance of Reference Example Indirubin (0.2%) was used. The results are shown in Table 1 and FIG.
[0020]
[Table 1]
[0021]
As is clear from Table 1, the extract of Ebine MeOH significantly increased rat skin blood flow in both 0.5% and 2.0%. Moreover, as shown in FIG. 1, the currant side A of the present invention significantly increased skin blood flow in 20 minutes. Indirubin has a similar stimulating effect but is not significant.
[0022]
[Test Example 2]
(Whitening effect)
According to the method of Mason and Peterson, the experiment was performed as follows. Specifically, 0.5 ml of L-dopa solution (0.03% in pH 6.8 PBS) was added to 0.5 ml of the test solution, incubated at 25 ° C. for 10 minutes, and further mushroom-derived tyrosinase solution (in pH 6.8 PBS, 45 U / ml) 0.5 ml was added and incubated at 25 ° C. for 5 minutes. Absorbance (D1) at 475 nm was measured after the reaction. Separately, the same operation was performed without adding the L-dopa solution, the absorbance (D2) was measured, and the absorbance (D3) as the amount of dopachrome produced without the addition of the test drug was measured. Using these D1, D2 and D3, the inhibition rate of dopachrome production was determined by the following formula and used as an index of tyrosinase activity. Examples of the test solution include Ebine MeOH extract of Example (CDM-ext), Ethyl acetate layer transfer part (AcOEtphase), Aqueous layer transfer part (H 2 Ophase), Currantside A (CDH2) of the present invention, As a control group, the positive control drug kojic acid was used. The results are shown in Table 2.
[0023]
[Formula 1]
[0024]
[Table 2]
[0025]
As is clear from Table 2, the extract of Ebine MeOH, the ethyl acetate layer transition part, and the aqueous layer transition part all showed strong anti-tyrosinase activity in a dose-dependent manner. Kojic acid in the positive control group also showed strong anti-tyrosinase activity. Considering the yield, the active ingredient for anti-tyrosinase activity is considered to be mainly in the water layer transition part, but the currantside A of the present invention also showed relatively strong anti-tyrosinase activity as shown in Table 3. .
[0026]
【The invention's effect】
According to the present invention, the new currant side A has a skin blood flow promoting action, and useful applications such as a hair restorer can be expected. Moreover, the skin whitening effect is also recognized and the use for cosmetics etc. is also possible.
[Brief description of the drawings]
FIG. 1 is a graph showing the rat skin blood flow promoting effect of currantside A and indirubin isolated from ebinelan.
[Chemical 1] [Chemical 2] [Chemical 3] [Formula 4] [Chemical formula 5] [Expression 1] [Table 1] [Table 2] [Table 3]
Claims (1)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11330497A JP3890544B2 (en) | 1997-03-25 | 1997-03-25 | New indole glycosides |
US09/030,732 US6297363B1 (en) | 1993-02-12 | 1998-02-25 | Glycoside indoles |
US09/030,730 US5997874A (en) | 1996-06-12 | 1998-02-25 | Dihydrophenanthrene |
US09/611,422 US6380168B1 (en) | 1996-06-12 | 2000-07-07 | Method for promoting hair growth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11330497A JP3890544B2 (en) | 1997-03-25 | 1997-03-25 | New indole glycosides |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10265492A JPH10265492A (en) | 1998-10-06 |
JP3890544B2 true JP3890544B2 (en) | 2007-03-07 |
Family
ID=14608844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11330497A Expired - Lifetime JP3890544B2 (en) | 1993-02-12 | 1997-03-25 | New indole glycosides |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3890544B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056384A1 (en) * | 2000-02-07 | 2001-08-09 | Hampshire Chemical Corp. | Methods for treating plants and enhancing plant growth with conjugated indoles and formulations for same |
KR100389983B1 (en) * | 2001-01-10 | 2003-07-04 | 바이오스펙트럼 주식회사 | Skin whitening composition containing arbutin and glucosidase as active ingredients |
JP2005179216A (en) * | 2003-12-17 | 2005-07-07 | Nomura:Kk | Indican-containing skin care preparation for external use |
JP2005179217A (en) * | 2003-12-17 | 2005-07-07 | Nomura:Kk | Bleaching agent |
JP2005179218A (en) * | 2003-12-17 | 2005-07-07 | Nomura:Kk | Skin care preparation for external use containing mercaptoindole derivative |
JP6856223B2 (en) * | 2018-05-15 | 2021-04-07 | 株式会社ノムラ | Composition for human dermal papilla cell proliferation |
-
1997
- 1997-03-25 JP JP11330497A patent/JP3890544B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH10265492A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Tommasi et al. | Hypoglycemic effects of sesquiterpene glycosides and polyhydroxylated triterpenoids of Eriobotrya japonica | |
US6380168B1 (en) | Method for promoting hair growth | |
KR100862968B1 (en) | Agents for Improving Wrinkles on Skin Comprising Matrine or Its Oxidized Derivatives | |
Matsuda et al. | Medicinal flowers. VIII. Radical scavenging constituents from the flowers of Prunus mume: structure of prunose III | |
Ibrahim et al. | A comparative study of the flavonoids and some biological activities of two Chenopodium species | |
Ravikumar et al. | Cytotoxic saponins from the Chinese herbal drug Yunnan Bai Yao | |
WO2003080634A1 (en) | Novel glucopyranoside and a process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof | |
Li et al. | Triterpenoid saponins and anti-inflammatory activity of Codonopsis lanceolata | |
JP3890544B2 (en) | New indole glycosides | |
US6777392B2 (en) | 8-(C-β-D-glucopyranosyl)-7, 3', 4'-trihydroxyflavone, process of isolation thereof, pharmaceutical composition and method for the treatment of diabetes | |
Choi et al. | Triterpenoid glycosides from the roots of Patrinia scabiosaefolia | |
JP3890545B2 (en) | New indole glycosides | |
Kikuchi et al. | Studies on the Constituents of Swertia japonica M AKINO II. On the Structures of New Glycosides | |
JPS6212791A (en) | Astragali radix saponin, isolation and use thereof | |
KR101047588B1 (en) | Whitening composition comprising white rice extract and novel pregnan compound isolated therefrom as active ingredient | |
Hasegawa et al. | Isolation and structure of magnoloside A, a new phenylpropanoid glycoside from Magnolia obovata Thunb. | |
KR20190089309A (en) | Method for producing esculetin using acid hydrolysis | |
CN110922444B (en) | Panaxadiol type triterpenoid saponin with anti-inflammatory activity | |
SAWABE et al. | Structures and hypotensive effect of flavonoid glycosides in young Citrus unshiu peelings | |
JP2002193990A (en) | Hydrochalcone glycoside and cosmetic formulated with the same as effective component | |
Seong et al. | Phenylacylphenol derivatives with anti-melanogenic activity from Stewartia pseudocamellia | |
KR101259496B1 (en) | Silkworm droppings extracts having anti-inflammatory effect and skin external compositions including the same | |
KR101201877B1 (en) | Silkworm droppings extracts having anti-inflammatory effect and skin external compositions including the same | |
JP5761743B2 (en) | Topical skin preparation | |
JPH0580449B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061124 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101215 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111215 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111215 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121215 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131215 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |